Duplicated Antistasin-Like Anticoagulant
Four-domain antistasin-like recombinant anticoagulant from H. medicinalis (Brovina 2026) — inhibits intrinsic + extrinsic + common pathway via aPTT / PT / TT.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Four-domain antistasin-like recombinant anticoagulant from H. medicinalis (Brovina 2026) — inhibits intrinsic + extrinsic + common pathway via aPTT / PT / TT.
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
The duplicated antistasin-like protein's in vitro broad coagulation inhibition does NOT establish clinical efficacy. No FDA-approved derivative exists; characterization remains at recombinant expression / clotting-assay stage.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 25,000 Da
- Source species
- Hirudo medicinalis
- Discovered
- 2026 · Brovina KA et al.
Biological Targets
- → intrinsic pathway
- → extrinsic pathway
- → common pathway
Key Citations
- Brovina KA et al. (2026), Biomolecules · PMID 41594695
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.